4I5M

Selective & Brain-Permeable Polo-like Kinase-2 (Plk-2) Inhibitors that Reduce -Synuclein Phosphorylation in Rat Brain


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.80 Å
  • R-Value Free: 0.392 
  • R-Value Work: 0.320 
  • R-Value Observed: 0.324 

wwPDB Validation   3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce alpha-synuclein phosphorylation in rat brain.

Aubele, D.L.Hom, R.K.Adler, M.Galemmo, R.A.Bowers, S.Truong, A.P.Pan, H.Beroza, P.Neitz, R.J.Yao, N.Lin, M.Tonn, G.Zhang, H.Bova, M.P.Ren, Z.Tam, D.Ruslim, L.Baker, J.Diep, L.Fitzgerald, K.Hoffman, J.Motter, R.Fauss, D.Tanaka, P.Dappen, M.Jagodzinski, J.Chan, W.Konradi, A.W.Latimer, L.Zhu, Y.L.Sham, H.L.Anderson, J.P.Bergeron, M.Artis, D.R.

(2013) ChemMedChem 8: 1295-1313

  • DOI: 10.1002/cmdc.201300166
  • Primary Citation of Related Structures:  
    4I5P, 4I5M, 4I6B, 4I6F, 4I6H

  • PubMed Abstract: 
  • Polo-like kinase-2 (Plk-2) has been implicated as the dominant kinase involved in the phosphorylation of α-synuclein in Lewy bodies, which are one of the hallmarks of Parkinson's disease neuropathology. Potent, selective, brain-penetrant inhibitors o ...

    Polo-like kinase-2 (Plk-2) has been implicated as the dominant kinase involved in the phosphorylation of α-synuclein in Lewy bodies, which are one of the hallmarks of Parkinson's disease neuropathology. Potent, selective, brain-penetrant inhibitors of Plk-2 were obtained from a structure-guided drug discovery approach driven by the first reported Plk-2-inhibitor complexes. The best of these compounds showed excellent isoform and kinome-wide selectivity, with physicochemical properties sufficient to interrogate the role of Plk-2 inhibition in vivo. One such compound significantly decreased phosphorylation of α-synuclein in rat brain upon oral administration and represents a useful probe for future studies of this therapeutic avenue toward the potential treatment of Parkinson's disease.


    Organizational Affiliation

    Molecular Discovery, Elan Pharmaceuticals, 180 Oyster Point Boulevard, South San Francisco, CA 94080, USA.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Serine/threonine-protein kinase PLK2A308Homo sapiensMutation(s): 7 
Gene Names: PLK2SNK
EC: 2.7.11.21
Find proteins for Q9NYY3 (Homo sapiens)
Explore Q9NYY3 
Go to UniProtKB:  Q9NYY3
NIH Common Fund Data Resources
PHAROS  Q9NYY3
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
R78
Query on R78

Download Ideal Coordinates CCD File 
A
4-{[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl]amino}-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide
C28 H39 N7 O3
XQVVPGYIWAGRNI-JOCHJYFZSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
R78IC50 :  8.800000190734863   nM  PDBBind
R78IC50:  8.800000190734863   nM  Binding MOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.80 Å
  • R-Value Free: 0.392 
  • R-Value Work: 0.320 
  • R-Value Observed: 0.324 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 104.329α = 90
b = 60.217β = 107.4
c = 53.213γ = 90
Software Package:
Software NamePurpose
HKL-2000data collection
AMoREphasing
REFMACrefinement
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report



Entry History 

Revision History 

  • Version 1.0: 2013-12-25
    Type: Initial release
  • Version 1.1: 2014-10-08
    Changes: Structure summary